Thrombolysis research - New objectives after a shift of accent

Medical Science Monitor

Volumn 8, Issue 1, 2002, Pages

  Maksimenko, Alexander V ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Adjacent agents; Clinical and experimental thrombolysis; Combined thrombolytic therapy; Conjunctive therapy; New thrombolytic regimen; Plasminogen activators; Prehospital emergency medical aid

Indexed keywords

FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; FIBRINOLYTIC THERAPY; HUMAN; MEDICAL RESEARCH; REVIEW; THROMBOSIS; TREATMENT OUTCOME;

ANTIOXIDANTS; CORONARY DISEASE; HUMANS; MODELS, BIOLOGICAL; PLASMINOGEN ACTIVATORS; THROMBOLYTIC THERAPY;

EID: 0036166360     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Cardiology: Where to go from here?
2. Pre-hospital and hospital time delays in thrombolytic treatment in patients with suspended acute myocardial infarction
3. Delays in thrombolytic therapy for acute myocardial infarction in Finland. Results of a national thrombolytic therapy delay study
4. The 60 minutes myocardial infarction project. Characteristics on admission and clinical outcome in patients with reinfarction compared to patients with a first infarction
5. Time delays in starting thrombolytic therapy
6. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens
7. Timely thrombolysis: Synergism to open arteries and reduce mortality rates
8. Have we reached the limit of thrombolytic therapy?
9. The effect of tissue plasminogen activator, streptokinase or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
10. Effect of prehospital thrombolysis on aborting acute myocardial infarction
11. Mortality and prehospital thrombolysis for acute myocardial infarction. A meta-analysis
12. The ideal fibrinolytic: Can drug design improve clinical results?
13. Targeting of thrombolytic and antithrombotic agents
14. Third-generation plasminogen activators: A new direction in research
15. What do new lytics add to t-PA?
16. Future of reperfusion therapy for acute myocardial infarction
17. Novel thrombolytic agents
18. Mutant and hybrid protein derivatives for the experimental therapy with plasminogen activators
19. Molecular interactions in fibrinolysis. Search for new plasminogen activators
20. Fibrin-selective thrombolytic therapy for acute myocardial infarction
21. Recent developments in thrombolytic therapy
22. DSPA-alpha properties of plasminogen activator of vampire bat Desmodus rotundus
23. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase
24. Thrombolysis for acute myocardial infarction
25. The current role of thrombolytic therapy in the treatment of acute myocardial infarction
26. Conjunctive thrombolysis under action of tissue-type plasminogen activator and conjugate urokinase-fibrinogen after double sequential bolus administration in the model of vein thrombosis in dogs
27. New thrombolytic strategy: Bolus administration of tPA and urokinase-fibrinogen conjugate
28. New strategy of thrombolysis. Conjunctive effect of plasminogen activators with different pharmacokinetic profile
29. Major mechanistic differences explain the higher dot lysis potency of reteplase over alteplase: Lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics
30. Molecular transport during fibrin dot lysis
31. Intravenous NPA for the treatment of infarcting myocardium early. In TIME-II, a double-blind comparison of single bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction
32. The beneficial effect of Lysplasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis
33. Enhancement of the thrombolytic efficacy of prourokinase by Lys-plasminogen in a dog model of arterial thrombosis
34. Recombinant Lys-plasminogen, but not Glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs
35. Recombinant Lysplasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: Relation ship of thrombolytic efficacy with parameters of fibrinolysis
36. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
37. Fibrinogen-immobilized urokinase demonstrates increased thrombolytic activity in animal experiments
38. Polyethylene glycolderivated cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction
39. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis
40. In TIME-II more than a study on lanoteplase
41. Evidence-based medicine and reteplase: Inductive arguments over deductive reasoning
42. Thrombolytic therapy in acute myocardial infaction
43. Complicated simplification of dosage regimen for plasminogen activators
44. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: A pooled analysis
45. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial
46. Thrombolysis medication error: Benefits of bolus thrombolytic agent
47. A randomized trial comparing primary angioplasty in acute myocardial infarction: The PACT trial
48. Combination therapy for acute myocardial infarction
49. Selection of thrombolytic therapy for individual patients: Development of a clinical model
50. New antithrombotic agents
51. New antithrombotic and antiplatelet treatment
52. Platelet glycoprotein IIb/IIIa inhibitors. Basic and clinical aspects
53. Antiplatelet drugs in the acute phase of myocardial infarction
54. Thrombolysis, antithrombotic agents, and antithrombotic approach in cardiac disease
55. Specific thrombin inhibitors only one tool of the antithrombotic armamentarium
56. Overcoming thrombolytic resistance. Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
57. Reperfusion injury: Experimental evidence and clinical implications
58. Antioxidants and vitamins in your cardiac patient: Are they helpful?
59. The oxidative paradox. Another piece in the puzzle
60. Antithrombotic activity of the superoxide dismutase-chondroitin sulfate complexes in a rat model of arterial injury
61. New insight into pathophysiology of acute coronary occlusion
62. Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up
63. Enzymic reconstruction of glycosaminoglycan oligosaccharide chains using the transglycosylation reaction of bovine testicular hyaluronidase
64. Chemical modification of hyaluronidase regulates its inhibition by heparin
65. The resistance of dextran-modified hyaluronidase against the heparin inhibition
66. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs
67. Ischemia-reperfusioninjury at the microvascular level. Treatment of endothelin A-selective antagonist and evaluation by myocardial contrast echocardiography
68. Coronary disease. Acute myocardial infarction: Thrombolysis
69. Metalloproteases in remodelling of vascular extracellular matrix
70. Molecular interactions between the plasminogen/plasmin and matrix metalloproteainase systems
71. Tafi
72. Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion
73. Cardiology of the 21st century
74. Ultrasound imaging-guided noninvasive ultrasound thrombolysis. Preclinical results
75. Determinants of coronary blood flow after thrombolytic administration
76. Research on clot stabilization provides clues for improving thrombolytic therapy